{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:29:28Z","timestamp":1791595768764,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015660","name":"UCB Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.msard.2023.104760","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:14:13Z","timestamp":1683756853000},"page":"104760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)"],"prefix":"10.1016","volume":"75","author":[{"given":"M Isabel","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Panahloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","article-title":"Global and regional estimates of preeclampsia and eclampsia: a systematic review","volume":"170","author":"Abalos","year":"2013","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.msard.2023.104760_bib0002","unstructured":"Advanz Pharma, 2020. Methotrexate - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/511\/smpc. (Accessed October 2022)."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2023.104760_bib0003","first-page":"S491","article-title":"Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study","volume":"12","author":"Ahadi","year":"2021","journal-title":"Caspian J. Intern. Med."},{"key":"10.1016\/j.msard.2023.104760_bib0004","unstructured":"Alexion, 2021. Soliris - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/362\/smpc. (Accessed October 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420949808","article-title":"Gender issues of antibody-mediated diseases in neurology: (NMOSD\/autoimmune encephalitis\/MG)","volume":"13","author":"Altintas","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104760_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102252","article-title":"Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder","volume":"44","author":"Ashtari","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2023.104760_bib0007","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.neurol.2018.01.373","article-title":"Neuromyelitis optica spectrum disorder and menstruation","volume":"174","author":"Badihian","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0008","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104760_bib0009","unstructured":"Beacon Pharmaceuticals, 2017. Methylprednisolone - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/5993\/smpc\/. (Accessed October 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0010","unstructured":"Bio Products, 2022. Gammaplex - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/4471\/smpc\/. (Accessed October 2022)."},{"issue":"8","key":"10.1016\/j.msard.2023.104760_bib0011","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1352458516671203","article-title":"Influence of female sex and fertile age on neuromyelitis optica spectrum disorders","volume":"23","author":"Borisow","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0012","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104760_bib0013","article-title":"Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease","author":"Carra-Dalliere","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104760_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2018.01.040","article-title":"Study of the placentae of patients with neuromyelitis optica spectrum disorder","volume":"387","author":"Chang","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2023.104760_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies","volume":"5","author":"Chen","year":"2016","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.msard.2023.104760_bib0017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.msard.2023.104760_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102399","article-title":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104760_bib0019","unstructured":"ClinicalTrials.gov, 2022. French Registry for Monitoring Pregnancies for Multiple Sclerosis (RESPONSE). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03900221. (Accessed October 2022)."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2023.104760_bib0021","doi-asserted-by":"crossref","first-page":"e2006","DOI":"10.1212\/WNL.0000000000011744","article-title":"Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder","volume":"96","author":"Collongues","year":"2021","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2023.104760_bib0022","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0023","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"S2","key":"10.1016\/j.msard.2023.104760_bib0024","first-page":"417","article-title":"Influence of pregnancy on disease progression and activity of neuromyelitis optica spectrum disorder (NMOSD) among seropositive female patients In Isfahan, Iran","volume":"25","author":"Dastjerdi","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2023.104760_bib0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.msard.2018.08.015","article-title":"Obstetric outcomes in a Mexican cohort of patients with AQP4-antibody-seropositive neuromyelitis optica","volume":"25","author":"Delgado-Garcia","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","article-title":"Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study","volume":"19","author":"Demuth","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1352458519895236","article-title":"MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary","volume":"26","author":"Fujihara","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104760_bib0028","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1212\/CPJ.0000000000001147","article-title":"Use of B-cell-depleting therapy in women of childbearing potential with multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"12","author":"Galati","year":"2022","journal-title":"Neurol. Clin. Pract."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0029","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12916-018-1128-1","article-title":"Gestational weight gain across continents and ethnicity: systematic review and meta-analysis of maternal and infant outcomes in more than one million women","volume":"16","author":"Goldstein","year":"2018","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment","volume":"35","author":"Gospe","year":"2021","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/cen3.12630","article-title":"Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G\u2013associated disease","volume":"12","author":"Healy","year":"2021","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.104760_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420945135","article-title":"Recent developments in MOG-IgG associated neurological disorders","volume":"13","author":"Hegen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104760_bib0034","unstructured":"Horizon Therapeutics, 2022. Uplizna - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/uplizna-epar-product-information_en.pdf. (Accessed December 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jns.2016.11.054","article-title":"Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China","volume":"372","author":"Huang","year":"2017","journal-title":"J. Neurol. Sci"},{"issue":"11","key":"10.1016\/j.msard.2023.104760_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.msard.2023.104760_bib0037","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2023.104760_bib0038","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.104760_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/2325958220903574","article-title":"Transition from pediatric to adult HIV care for young women living with HIV","volume":"19","author":"Kennedy","year":"2020","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"issue":"537","key":"10.1016\/j.msard.2023.104760_bib0040","article-title":"Relapse Patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","volume":"11","author":"Khalilidehkordi","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2023.104760_bib0041","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/ene.14274","article-title":"Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder","volume":"27","author":"Kim","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"16","key":"10.1016\/j.msard.2023.104760_bib0042","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.msard.2023.104760_bib0043","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"22","key":"10.1016\/j.msard.2023.104760_bib0044","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0045","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany","volume":"8","author":"K\u00fcmpfel","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.msard.2023.104760_bib0046","first-page":"1103","article-title":"Stress, adverse pregnancy outcomes, and African-American females","volume":"95","author":"Livingston","year":"2003","journal-title":"J. Natl. Med. Assoc."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000095","article-title":"Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss","volume":"2","author":"Mankee","year":"2015","journal-title":"Lupus Sci. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0048","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104760_bib0049","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104760_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.yebeh.2016.11.008","article-title":"Treatment issues for children with epilepsy transitioning to adult care","volume":"69","author":"Nabbout","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.msard.2023.104760_bib0051","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2023.104760_bib0052","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0053","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2023.104760_bib0054","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2023.104760_bib0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104760_bib0056","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104760_bib0057","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/AOG.0000000000003730","article-title":"Adverse infant and maternal outcomes among low-risk term pregnancies stratified by race and ethnicity","volume":"135","author":"Parchem","year":"2020","journal-title":"Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.msard.2023.104760_bib0058","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2023.104760_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.msard.2023.104760_bib0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104760_bib0061","unstructured":"Roche, 2021. Enspryng - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enspryng-epar-product-information_en.pdf. (Accessed December 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0062","unstructured":"Roche, 2021. MabThera - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/3801\/smpc\/. (Accessed October 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0063","unstructured":"Roche, 2022. Cellcept - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/1102\/smpc\/. (Accessed October 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0064","unstructured":"Roche, 2022. RoActemra - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf. (Accessed December 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2019.05.007","article-title":"Neuromyelitis optica and pregnancy-puerperal cycle","volume":"34","author":"Salvador","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0066","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.msard.2023.104760_bib0067","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.msard.2023.104760_bib0068","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2017.03.051","article-title":"Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy","volume":"377","author":"Shi","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.msard.2023.104760_bib0069","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Shimizu","year":"2016","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2023.104760_bib0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Socie","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2023.104760_bib0071","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104760_bib0072","unstructured":"Tillomed Laboratories, 2022. Azathioprine - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/11143\/smpc\/. (Accessed October 2022)."},{"key":"10.1016\/j.msard.2023.104760_bib0073","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.07.006","article-title":"Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis","volume":"25","author":"Tong","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.104760_bib0074","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104760_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2018.02.006","article-title":"MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis","volume":"21","author":"Vecchio","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104760_bib0076","first-page":"140","article-title":"Pregnancy outcomes in neuromyelitis optica spectrum disorder","volume":"28","author":"Vishnevetsky","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2023.104760_bib0077","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/13524585221130934","article-title":"Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society","volume":"29","author":"Vukusic","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104760_bib0078","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-323982","article-title":"Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors","author":"Wang","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104760_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2023.104760_bib0080","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2023.104760_bib0081","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.4187\/respcare.08260","article-title":"Transition from pediatric to adult care for young adults with chronic respiratory disease","volume":"65","author":"Willis","year":"2020","journal-title":"Respir. Care"},{"issue":"2","key":"10.1016\/j.msard.2023.104760_bib0082","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2023.104760_bib0083","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2023.104760_bib0084","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104760_bib0085","unstructured":"Wockhardt UK, 2021. Prednisolone - Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/2427\/smpc\/. (Accessed October 2022)."},{"issue":"5","key":"10.1016\/j.msard.2023.104760_bib0086","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J. Neurol."},{"issue":"22","key":"10.1016\/j.msard.2023.104760_bib0087","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104760_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577093","article-title":"Sexual dysfunction in patients with neuromyelitis optica spectrum disorder","volume":"338","author":"Zhang","year":"2020","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:18Z","timestamp":1761901578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":87,"alternative-id":["S2211034823002638"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104760","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 UCB Pharma. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104760"}}